GYRE Profile
Gyre Therapeutics Inc., headquartered in San Diego, California, is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for metabolic and liver diseases. The company's primary focus is on Hydronidone (F351), a novel therapeutic agent being developed for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH), a condition previously known as Nonalcoholic Steatohepatitis (NASH). MASH is characterized by liver fibrosis and inflammation associated with metabolic dysfunction, and Hydronidone is being evaluated for its efficacy in addressing this condition.
Hydronidone is currently under investigation for its potential to treat liver fibrosis across a broad range of chronic liver diseases, supported by an active Investigational New Drug (IND) application in the United States. This research aims to provide new therapeutic options for patients suffering from advanced liver conditions, which are often resistant to current treatments.
In addition to its work with Hydronidone, Gyre Therapeutics is expanding its research efforts through a diverse pipeline of drug candidates in China. The company holds a controlling interest in Beijing Continent, which facilitates the development and commercialization of several additional therapies. This includes pirfenidone, a drug under development for its antifibrotic properties, as well as F573, F528, and F230, which are being explored for their potential to treat various other conditions.
Founded with a vision to advance cutting-edge treatments for complex diseases, Gyre Therapeutics continues to leverage its scientific expertise and global partnerships to drive innovation in the biopharmaceutical field. The company's commitment to addressing unmet medical needs and expanding its research footprint underscores its role as a key player in the development of novel therapies for metabolic and liver diseases.
|
